Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 482

1.

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K.

J Biol Chem. 2005 Jul 22;280(29):26729-34. Epub 2005 Jun 2.

2.

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K.

Blood. 2008 Sep 1;112(5):1886-93. doi: 10.1182/blood-2008-03-143644. Epub 2008 Jun 30.

3.

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K.

Blood. 2005 Feb 15;105(4):1768-76. Epub 2004 Oct 28.

4.
5.

FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.

Wang Y, Wang SY, Zhang XH, Zhao M, Hou CM, Xu YJ, Du ZY, Yu XD.

Biochem Biophys Res Commun. 2007 May 18;356(4):998-1003. Epub 2007 Mar 22.

PMID:
17397803
6.

Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.

Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH.

J Pharmacol Exp Ther. 2007 Sep;322(3):1084-92. Epub 2007 Jun 14.

7.

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.

Cancer Res. 2003 Aug 15;63(16):5126-35.

8.

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K.

Blood. 2008 Oct 1;112(7):2896-905. doi: 10.1182/blood-2007-10-116319. Epub 2008 Jul 25.

9.

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.

Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.

Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.

10.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

11.

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP.

Mol Cell. 2005 May 27;18(5):601-7.

12.

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.

Leuk Res. 2008 Sep;32(9):1382-92. doi: 10.1016/j.leukres.2008.02.018. Epub 2008 Apr 3.

PMID:
18394702
13.
14.

The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.

Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, De Tommasi N, Zunino F.

Cell Mol Life Sci. 2010 Mar;67(6):995-1004. doi: 10.1007/s00018-009-0233-x. Epub 2009 Dec 29.

PMID:
20039095
15.

Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.

Sasaki K, Yamagata T, Mitani K.

Cancer Sci. 2008 Feb;99(2):414-22. doi: 10.1111/j.1349-7006.2007.00699.x.

16.

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.

Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, Hyun YL, Choi J.

Breast Cancer Res Treat. 2011 Nov;130(2):365-75. doi: 10.1007/s10549-010-1310-4. Epub 2010 Dec 24.

PMID:
21184271
17.

A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation.

Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, Workman P, Aherne W.

Mol Cancer Ther. 2007 Mar;6(3):1112-22.

18.

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K.

Blood. 2006 Jul 15;108(2):645-52. Epub 2006 Mar 14.

20.

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase.

Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, Kim DK, Bang YJ, Kim TY.

J Mol Med (Berl). 2008 Jan;86(1):117-28. Epub 2007 Sep 13.

PMID:
17851643
Items per page

Supplemental Content

Write to the Help Desk